SHL pumps $40M into Taiwan delivery industry; FDA grants melphalan orphan status to beleaguered Delcath;

@MichaelGFierce: Vaginal polymer ring delivers long-term HIV-preventing drug. Item | Follow @MichaelGFierce

> Drug delivery devicemaker SHL is investing $40 million in Taiwan, signing a letter of intent with the Taiwan Ministry of Economic Affairs. Story

> The FDA granted Delcath Systems orphan drug designation for the use of melphalan hydrochloride in patients with hepatocellular carcinoma, or primary liver cancer. The company has had trouble with its delivery system for liver cancer in the past. Release

> InSite Vision enrolled patients in a Phase III clinical trial of its BromSite for the reduction of inflammation and pain after cataract surgery. The combination uses the company's InSite delivery tech to deliver a non-steroidal anti-inflammatory. Release

> Austin, TX-based Mystic Pharmaceuticals snagged patent application notices in China and Japan for its dosage-controlling delivery systems. More

> ProStrakan launched its Sancuso transdermal delivery system in Europe with approval from the European Medicines Agency. The company will team with 3M Drug Delivery Systems as a manufacturer. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.